Intramural Grant Programs

 

Intramural Grant Programs

Centers and offices administer intramural research funding programs focused on a variety of topics and use different mechanisms, such as small competitive grant program.

In response to the growing number of cross-cutting science and technological issues arising from regulatory oversight of products in FDA’s regulatory portfolio (i.e., see FARS for most current list of such regulatory science focus areas that have been identified by FDA), FDA developed a competitive grants program called the OCS Intramural Challenge Grants to foster opportunities for cross-center and office cooperation and collaboration and to serve as an incubator for innovative ideas.

FDA’s Chief Scientist establishes highly innovative and high-risk projects that reflect FDA’s overarching regulatory science focus areas including:

• Collaborative Opportunities for Research Excellence in Science champions FDA cross-center regulatory research nanotechnology efforts
• Office of Women’s Health Intramural Grants Program aims to address gaps in current regulatory knowledge, set new directions in regulatory policies, or establish a new standard of excellence for research in women’s health and sex differences.
• Medical Countermeasures Initiative leads projects that address regulatory science gaps for countermeasures against chemical, biological, and radiological/nuclear threats and emerging infectious diseases.
• Perinatal Health Center of Excellence Intramural Funding Program applies research to understudied populations of the perinatal period (maternal, premature, neonatal and pediatric periods, as well as development throughout childhood).

 

 

CROSS-CUTTING TOPICS

Minority Health and Health Equity	Women’s Health	Maternal Health	Pediatric Health
Oncology	Rare Diseases	One Health Initiative

 

EXPLORE THE FOCUS AREAS OF REGULATORY SCIENCE

Advanced Manufacturing	Antimicrobial Resistance	Artificial Intelligence	Biomarkers
Complex Innovative Trial Design	Digital Health Technologies	Empowering Patients and Consumers to Make Better-Informed Decisions	Food Safety
Increasing Access to Complex Generic Drug Products	Individualized Therapeutics and Precision Medicine	Medical Countermeasures and Preparedness for Emerging Infectious Diseases	Microbiome Research
Model-Informed Product Development	Novel Foods and Food Ingredients	Novel Technologies to Improve Predictivity of Non-clinical Studies and Replace, Reduce, and Refine Reliance on Animal Testing	Patient and Consumer Preferences and Perspectives
Patient-Reported Outcomes and other Clinical Outcome Assessments	Product Safety Surveillance	Quality of Compounded Drugs	Regenerative Medicine
	Substance Use Disorders	Technologies to Reduce Pathogen Contamination	Use of Real-World Evidence to Support Biologic, Device, and Drug Development and Regulatory Decision-Making

 

Research Capabilities, Tools, and Resources

Research Management and Collaborations

Technology Transfer and Public-Private Partnerships

Physical Standards and Reference Materials

Intramural Grant Programs

Extramural Funding Mechanisms

Scientific Education, Training, and Communication

Fellowship and Training Opportunities

Professional Development and Continuing Education

Communication and External Meetings

Infrastructure

Facilities and Shared Resources

Safety and Compliance

 

ADDITIONAL ORGANIZATIONAL INFORMATION

Office of the Chief Scientist

Office of Regulatory Science and Innovation

Contact Us: FARS@fda.hhs.gov